2/7/2012

The FDA reopened the comment period on its proposed rule for direct-to-consumer marketing of prescription drugs.
The decision follows release of an agency-sponsored study that assessed the impact of distracting images or statements in ads on consumers' understanding of information about drug risks and benefits.

Full Story:
Xconomy

Related Summaries